Table 2.
Peptides used for HLA multimer analysis of virus-specific CD8+ T cells.
| CMV No. |
Abbr. | Full Sequence | Protein | HLA Restriction |
Reference |
|---|---|---|---|---|---|
| 1 | VTE | VTEHDTLLY | pp50 | A*01:01 | Elkington et al. 2003 (21) |
| 2 | YSE | YSEHPTFTSQY | pp65 | A*01:01 | Longmate et al. 2001 (22) |
| 3 | NLV | NLVPMVATV | pp65 | A*02:01 | Diamond et al. 1997 (23) |
| 4 | VLE | VLEETSVML | IE-1 | A*02:01 | Khan et al. 2002 (24) |
| 5 | TPR | TPRVTGGGAM | pp65 | B*07:02 | Weekes et al. 1999 (25) |
| 6 | RPH | RPHERNGFTVL | pp65 | B*07:02 | Weekes et al. 1999 (25) |
| 7 | ELK | ELKRKMMYM | IE-1 | B*08:01 | Elkington et al. 2003 (21) |
| 8 | QIK | QIKVRVDMV | IE-1 | B*08:01 | Elkington et al. 2003 (21) |
| 9 | IPS | IPSINVHHY | pp65 | B*35:01 | Gavin et al. 1993 (26) |
| 10 | CRV | CRVLCCYVL | IE-1 | C*07:02 | Ameres et al. 2013 (27) |
| EBV No. |
Abbr. | Full Sequence | Protein | HLA Restriction | Reference |
| 1 | CLG | CLGGLLTMV | LMP2 | A*02:01 | Lee et al. 1993 (28) |
| 2 | GLC | GLCTLVAML | BMLF1 | A*02:01 | Steven et al. 1997 (29) |
| 3 | YVL | YVLDHLIVV | BRLF1 | A*02:01 | Saulquin et al. 2000 (30) |
| 4 | FLY | FLYALALLL | LMP2 | A*02:01 | Meij et al. 2002 (31) |
| 5 | RPP | RPPIFIRRL | EBNA3A | B*07:02 | Hill et al. 1995 (32) |
| 6 | QAK | QAKWRLQTL | EBNA3A | B*08:01 | Burrows et al. 1994 (33) |
| 7 | RAK | RAKFKQLL | BZLF1 | B*08:01 | Bogedain et al. 1995 (34) |
| 8 | YPL | YPLHEQHGM | EBNA3A | B*35:01 | Burrows et al. 1994 (33) |
| 9 | HPV | HPVGEADYFEY | EBNA1 | B*35:01 | Rickinson et al. 1997 (35) |
| 10 | EPL | EPLPQGQLTAY | BZLF1 | B*35:01 | Saulquin et al. 2000 (30) |
To assess the presence of CMV/EBV specific CD8+ T cells before and after the T cell product application flow cytometric analysis using peptide loaded HLA multimers was used. The HLA multimers used were selected according to the presence of the HLA genotype of the patient.